• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma

    2021-12-03 06:15:24HiromitsuHayashiNorioUemuraKazukiMatsumuraLiuZhaoHirokiSatoYutaShiraishiYoichiYamashitaHideoBaba
    World Journal of Gastroenterology 2021年43期

    Hiromitsu Hayashi, Norio Uemura, Kazuki Matsumura, Liu Zhao, Hiroki Sato, Yuta Shiraishi, Yo-ichi Yamashita, Hideo Baba

    Abstract Pancreatic ductal adenocarcinoma (PDAC) remains the most lethal type of cancer.The 5 -year survival rate for patients with early-stage diagnosis can be as high as 20 %, suggesting that early diagnosis plays a pivotal role in the prognostic improvement of PDAC cases. In the medical field, the broad availability of biomedical data has led to the advent of the “big data” era. To overcome this deadly disease, how to fully exploit big data is a new challenge in the era of precision medicine. Artificial intelligence (AI) is the ability of a machine to learn and display intelligence to solve problems. AI can help to transform big data into clinically actionable insights more efficiently, reduce inevitable errors to improve diagnostic accuracy, and make real-time predictions. AI-based omics analyses will become the next alterative approach to overcome this poor-prognostic disease by discovering biomarkers for early detection, providing molecular/genomic subtyping, offering treatment guidance, and predicting recurrence and survival.Advances in AI may therefore improve PDAC survival outcomes in the near future. The present review mainly focuses on recent advances of AI in PDAC for clinicians. We believe that breakthroughs will soon emerge to fight this deadly disease using AI-navigated precision medicine.

    Key Words: Pancreatic cancer; Pancreatic ductal adenocarcinoma; Artificial intelligence;Machine learning; Precision medicine

    INTRODUCTION

    Pancreatic ductal adenocarcinoma (PDAC) stands the most life-threatenning type of cancer[1]. The recent 5 -year survival rate for PDAC in all stages is 8 .5 % according to American Cancer Society statistics 2017 . In patients with early-stage diagnosis, the 5 -year survival rate for can be as high as 20 %. During the past ten years, median overall survival (OS) has improved from 22 .1 mo to 35 mo in resectable PDAC, considerably owing to improvements in adjuvant therapies[2 -5]. These findings suggest that early diagnosis plays a pivotal role in the prognostic improvement of PDAC cases.Furthermore, the high recurrence rate, even in patients who have undergone curative resection, and chemoresistance to the current systemic chemotherapies (FOLFIRINOX:5 -fluorouracil, folinic acid, irinotecan, and oxaliplatin; and GnP: Gemcitabine plus nabpaclitaxel)[6 ,7] are major issues. Based on recent advances in genetic analysis, PDACs have been divided into several molecular subtypes[8 -11], which is a prelude of precision medicine. Genetic and molecular profiling researches have revealed that up to 25 % (range 12 %-25 %) of PDACs maintained actionable molecular alterations.Actually, matching to relevant molecular-specific treatments improves the OS compared to that of those without actionable mutations or those who do not receive molecular-specific therapy[12]. The comprehensive biomedical data has led to the dawn of the “big data” era in the medical field[13].

    To overcome this deadly disease, how to well utilize big data is a next step for physicians and researchers physicians in the era of precision medicine. The main issue for physicians has shifted from gathering data to competently analyzing it. Artificial intelligence (AI) is the ability of a machine to learn and display intelligence to solve problems (Figure 1 )[14]. An artificial neural network (ANN) can imitate the human neural meridian system. It is divided into three parts: Input layer, hidden layer, and output layer. “Deep learning” refers to an ANN with multiple hidden layers. Machine learning helps researchers spend less time on data processing. The processess for employing machine learning generally contain the following: Gathering the basic data,separating the data into an experimental group and a verification group, buildinging a screening and processing model, inputting the experimental group data into the model, accounting the output results, and confirming the model’s workability using the verification group. The verification group can be employed to examine the sensitivity and specificity of the experimental group, while the experimental group can fabricate more intelligent model. An overview of types in AI is provided in the Supplementary material. Chenet al[15] developed a survival prediction model of non-small cell lung cancer patients through the use of ANN. AI has also been applied to tackle and manage the recent coronavirus disease 2019 crisis in many areas, including screening, diagnosis, severity stratification, mortality prediction, and epidemiology controls[16].

    In the age of precision medicine, AI can support to convert big data into clinically actionable perception more conveniently, reduce the inevitable errors to improve diagnostic accuracy, and make real-time predictions[17 ,18]. Due to latest breakthroughs, the demand of AI in cancer treatment has been swiftly increasing, including for PDACs[19 -21]. Recent studies have demonstrated considerable potential for AI application in PDAC care (Table 1 ). Advances in AI for PDACs may thus be thealternative stream to improve survival outcomes for this deadly disease. The present review mainly focuses on recent advances of AI in PDAC care for clinicians.

    Table 1 Comprehensive list of artificial intelligence-based investigations in pancreatic ductal adenocarcinoma

    Molecular subtype Kaissis et al[68], 2020 CT Random forest 84920 .93 Tumor subtype (QM vs non-QM)Kaissis et al[67], 2019 MRI Gradient boosting decision tree 90920 .93 Molecular subtype (KRT81 positive vs negative)Microsatellite instability status Li et al[19], 2020 PreMSIm (15 -gene signature)k-NN 859795 AI: Artificial intelligence; PDAC: Pancreatic ductal adenocarcinoma; NA: Not available; ROC-AUC: Area under the receiver operating characteristic curve;ICD-9 : International Classification of Diseases 9 th Revision; ANN: Artificial neural network; CT: Computed tomography; DCNN: Deep convolutional neural network; EUS: Endoscopic ultrasound; NN: Neural network; CA19 -9 : Carbohydrate antigen 19 -9 ; IPA: Index of prediction accuracy; MRI: Magnetic resonance imaging; QM: Quasi-mesenchymal; PSO: Particle swarm optimization; NCA: Neighborhood components analysis; k-NN: k-Nearest neighbor.

    Figure 1 Differences among artificial intelligence, machine learning, neural network, and deep learning.

    PDAC RISK PREDICTION BY AI

    The radiographic traits of unoperability and the appearance of symptoms of PDAC occur concurrently[22]. At the time of diagnosis, only a small part of patients (< 15 %)have surgically resectable state[22]. In addition, identification of individuals at high risk for PDAC or with early stage is hard due to the absence of trusty screening tools,the lack of clinically relevant biomarkers, and low prevalence[22]. No established screening strategy has been introduced for sporadic PDAC. It is estimated that symptoms manifest about 6 mo after PDAC becomes unresectable[22]. Identifying individuals at high risk but asymptomatic is crucial for finding PDAC while it is still resectable.

    Approximately 50 % of all patients with PDAC develop diabetes mellitus prior to their diagnosis[23 ,24]. Screening patients with new-onset diabetes may enable earlier diagnosis of PDAC. In pre-diabetic and new-onset diabetic patients, an AI-based prediction model of PDAC risk has been developed[25 ,26]. In a pre-diabetic study, 245 of 138232 patients with impaired fasting glucose were thereafter diagnosed as having PDAC within 3 years of impaired fasting glucose detection. The AI (logistic regression model)-based prediction model consisted of age, body mass index, PPIs, total cholesterol, low-density lipoprotein, alanine transaminase, and alkaline phosphatase[25]. This model achieved an area under the curve (AUC) of 0 .71 . Furthermore, by analyzing 109 ,385 new-onset diabetic patients including 390 PDAC cases, a multivariable prediction (logistic regression) model that included age, smoking, body mass index, change in body mass index, usage of proton pump inhibitors and antidiabetic medications (insulin, oral hypoglycemic except metformin, and metformin), as well as levels of hemoglobin, hemoglobin A1 C, creatinine, cholesterol, and alkaline phosphatase, was established (AUC, 0 .82 )[26]. Among these diabetic patients, 390 (0 .4 %) were diagnosed with PDAC within 3 years. If the predicted risk threshold for definitive PDAC screening was set at 1 % over 3 years, only 6 .19 % of the new-onset diabetes cases would undergo definitive screening, which could identify PDAC cases with 94 .0 % specificity, 44 .7 % sensitivity, and a positive predictive value of 2 .6 %[26].

    Caiet al[27] established a PDAC risk prediction model by analyzing 138 chronic pancreatitis patients with focal mass lesions. A scoring method based logistic regression was employed to build the prediction model, which included five variables:sex, mass number, mass location, bilirubin, and carbohydrate antigen 19 -9 (CA19 -9 )(AUC, 0 .72 ). Hsieh et al[28] predicted PDAC in patients with type 2 diabetes using ICD-9 code data by logistic regression and ANN models. The AUCs achieved by these models were 0 .72 [27] and 0 .73 [28], respectively.

    Appelbaumet al[29] used a logistic regression model and developed a prediction model of PDAC using electronic health record data. A total of 18 risk factors (i.e., age,gender, race, abdominal pain, angina pectoris, asthma, atherosclerotic heart disease,calculus gallbladder, chest pain, chronic pancreatitis, coronary heart disease, diabetes mellitus, emphysema, essential hypertension, family history pancreatic cancer,jaundice, stroke, and ulcer) were used to weigh the risk factors, and their prediction model displayed an AUC of 0 .71 . Their risk model based on patients’ prior diagnoses derived from electronic health record data would predict PDAC 6 -12 mo before an eventual diagnosis date. Such a risk score could be employed as an initial screening prior to additional biomarkers or genetic testing, to pick out individuals from the general population for closer surveillance.

    Muhammadet al[30] used the ANN model to focus on the early prediction and stratification of PDAC risk based on personal health data (800114 answers in the National Health Interview Survey and Pancreatic, Lung, Colorectal, and Ovarian cancer datasets, including 898 cases diagnosed with pancreatic cancer) before symptoms appear. The prediction model using 18 personal health features produced a specificity of 80 .7 %, a sensitivity of 80 .7 %, and an AUC of 0 .85 to predict PDAC[30].Furthermore, the model based solely on personal health data was able to divide individuals into low, medium, and high cancer risk. Identification of high-risk individuals who would benefit from tailored screening may increase the probability of detecting early PDAC. While logistic regression was used to develop risk prediction models in many previous studies, Muhammadet al[30] employed an ANN model based on personal health big data and produced the highest AUC in the prediction model of PDAC risk.

    Such prediction models using AI will be beneficial for clinicians to estimate the PDAC risk of their patients easily after inputting their data. These models can be combined into an electronic medical record system or be available on portable devices such as tablets and mobile phones. They may also be useful for primary care physicians to stratify individuals into various risk categories. By such PDAC risk stratification, higher-risk individuals can be referred to a diagnostic department for more intensive and tailored assessments. More data and testing will be required to refine the performance of the AI-based prediction model of PDAC in order to facilitate its application in the clinical setting. An AI-based prediction model using clinical variables is non-invasive, cost-effective, and easy for early diagnosis of PDAC. Using AI to recognize signs in early PDAC and precancerous lesions is one of the key strategies to improving survival.

    DETECTION OF EARLY PDAC BY BIOMARKERS USING AI

    It is highly desirable to identify an effective PDAC diagnostic biomarker. Currently,the most widely employed biomarker for early PDAC detection is CA19 -9 , however it is not an perfect because of its comparatively low level of specificity and sensitivity(70 % with a 5 % error rate, for diagnosis of PDAC)[31 ,32]. Several molecular elements such as CA19 -9 , CEA, DUPAN, and Span-1 have been employed as biomarkers for diagnosis of pancreatic tumors[33], but none of them are sufficiently specific and sensitive to clearly distinguish cancer from healthy or benign diseases. Therefore, a solid tool with sufficient specificity and sensitivity is required to enable early PDAC diagnosis. Zhanget al[34] designed a novel AI (support vector machine) method based on relative gene expression ranking within tissue samples using the microarray gene expression data and RNA-seq data collected from two databases, GEO and TCGA.Zhanget al[34] then identified a qualitative diagnostic signature comprising 9 gene pairs (16 genes), that could distinguish PDAC (using expression profiles from PDAC and adjacent normal tissues) patients from non-PDAC (pancreatitis and normal tissues) and was a useful biomarker for early detection of PDAC. Seven genes in the nine-gene-pair signature, namely CTSE, HOXB7 , LAMC2 , ONECUT1 , RRM2 ,SERPINB5 , and UBE2 C, had previously been known to be associated with PDAC.Thus, AI-based tissue biomarker analysis identified a multiple-gene expression signature for detection of early PDAC.

    MicroRNAs (miRNAs) have been proposed as promising biomarkers for diagnosis of PDAC[35]. miRNAs are a group of short non-coding RNA molecules with 19 -25 nucleotides that have been considered as candidate biomarkers for early cancer diagnosis and precise prognosis[36]. Recently, miRNA-used liquid biopsy has become a promising approach for early detection of cancers. Several miRNAs in plasma of PDAC patients are abundantly expressed, supporting that circulating miRNAs could be helpful for PDAC detection[37]. Ganepola et al[38] employed three circulating miRNAs (miR-22 , miR-642 b-3 p, and miR-885 -5 ) for detection of PDAC, and the AUC value was 0 .97 for discrimination of the PDAC cases. Liu et al[39] utilized a serum panel including miR-20 a, miR-21 , miR-24 , miR-25 , miR-99 a, miR-185 , and miR-191 for diagnosis of PDAC at different stages, and the AUC value was 0 .99 . Alizadeh Savarehet al[40] assessed the value of top miRNAs using a machine learning method (particle swarm optimization + ANN + neighborhood components analysis) to assist early diagnosis of PDAC. They identified a number of serum miRNAs that were significantly differentially expressed in 671 microarray PDAC expression profiles,using bioinformatics techniques Their final model comprised the most promising miRNAs (miR-92 a-2 -5 p, miR-125 b-3 p, miR-532 e5 p, miR-663 a, and miR-1469 ) with the high performance (accuracy, 0 .93 ; sensitivity, 0 .93 ; and specificity, 0 .92 ) in differentiation of PDAC from controls.

    Early detection of PDAC using tissue and/or blood biomarkers in conjunction with AI is an alternative approach to improving survival.

    DETECTION OF EARLY PDAC BY RADIOMICS

    Nowadays, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, endoscopic ultrasound are the most popular imaging modalities for PDAC detection. However, these modalities are often employed in patients with symptoms,which results in delayed detection of PDACs in most cases. A promising application of AI technology is in the earlier detection of PDAC from radiological findings. CT is the most frequently used modality for the initial assessment of suspected PDAC, and its sensitivity of detection ranges from 76 %-96 %[41]. CT imaging can collect information about tumor location, size, and morphology. The pancreas is considerably different in size, shape, and location among the individuals and possesses only a very small part of the entire CT image, or about 1 .3 % of each CT image in a CT dataset[42]. Furthermore, a tumor shows high similarity to the surrounding tissues. Therefore, visual diagnosis demands doctors with enough clinical experience, because the quality of CT images varies between different CT scanners and operators, and pathological texture features are hard to distinguish. Actually, 19 % of patients with pancreatic cancer who underwent a review of submitted outside imaging and repeat imaging at a tertiary referral center received major changes in diagnosis and/or disease stage[43].

    The features of early PDAC can be delicate and retrospectively ascertained up to 34 mo before the diagnosis of PDAC[44]. In a tertiary medical center, 7 .1 % of PDACs were missed even by radiologist assessment. This fact emphasizes the limitations in the conventional CT approach for PDAC. Prognostic outcome in patients with PDACs considerably deteriorates when tumor size exceeds 2 cm[45], however tumors smaller than 2 cm are frequently invisible on CT images and so about 40 % of small PDACs are missed[46]. An AI-based diagnostic tool might minimize such oversight. Therefore,there is a growing need to develop AI-based algorithms for accurate pancreatic tumor detection. Although deep learning has been investigated for the diagnosis of pancreatic cystic neoplasms[47], neuroendocrine tumors[48] and segmentation of the pancreas[49 -52], the usefulness of AI in the detection of PDAC has not yet been widely explored. AI can analyze thousands of images on a pixel-by-pixel level and is not susceptible to mistakes due to human error. Another strength of AI is automatic diagnosis, which takes no more than approximately 20 s per case from inputting the original CT image to obtaining a diagnosis.

    Liuet al[53] reported that the AUC of an AI [convolutional neural network (CNN)]platform for CT-assisted diagnosis of PDAC was 0 .963 . Furthermore, the time of the CT-assisted diagnosis was 20 s/case, which is remarkably shorter than the duration required for diagnosis by radiologists, indicating AI has good clinical feasibility. In a deep learning (fully end-to-end deep learning) model for diagnosing pancreatic tumors, Siet al[42] reported that the average test time per case was 18 .6 s, compared with at least 8 min for manual reviewing. Thus, the AI diagnosis system was more efficient than the conventional diagnostic approach.

    Liuet al[54] showed that CNN-based analysis could precisely discriminate cases with and without PDAC in portal venous CT. The CNN-based analysis achieved an accuracy approaching 99 % and missed fewer tumors than did radiologists. In this study, CNN-based analysis provided higher sensitivity compared to radiologists(0 .983 vs 0 .929 , respectively)[54]. CNN missed three (1 .7 %) of 176 PDACs (1 .1 -1 .2 cm).Radiologists missed 12 (7 %) of 168 PDACs (1 .0 -3 .3 cm), of which 11 (92 %) were correctly classified by CNN. The sensitivity of CNN for tumors smaller than 2 cm was 92 .1 % in local test sets and 63 .1 % in an external (US) test set. Although the latter sensitivity for tumors smaller than 2 cm initially seemed unsatisfactory, DeWittet al[46] reported that the sensitivity of CT by radiologist assessment was 53 % for PDACs smaller than 2 .5 cm[46]. Consequently, the sensitivity of the CNN-based analysis was equivalent to radiologist assessment. The lower sensitivity of the CNN in the external test set compared with local test sets might be attributed to differences in patients'ethnicity and race, and protocols or scanners, between the training and external test sets, which could present greater challenges for small tumors. An important factor that affects the imaging features of the pancreas is fat content. Higher fat content decreases the density of the pancreas on CT images, and several studies reported marked differences in pancreatic fat content between ethnicities and races[55 ,56].

    Radiologists were given with important clinical information from the clinicians when they assessed the CT images, whereas the CNN was provided with no information except CT images. Therefore, the major utility of the CNN was to support radiologists in judging whether a lesion or suspicious area in the pancreas harbored pancreatic cancer. For example, patients present with obstructive jaundice which is a typical sign of pancreatic cancer in the pancreatic head. Nevertheless, the CT findings are negative or equivocal. In such a situation, occult pancreatic cancer should be highly suspected even if no apparent mass is noted on CT image, given that about 40 %of PDACs smaller than 2 cm are missed on CT image due to undefined borders with surrounding tissue[46 ,57].

    With the wide application of endoscopic ultrasonography (EUS) and EUS-fine needle aspiration (FNA) have become the important diagnostic modalities for PDAC;these modalities provide diagnostic accuracies up to 85 %, which are remarkably greater than the 50 % accuracy in CT-assisted diagnosis. The sensitivity of diagnosis of pancreatic tumors 3 cm in diameter was reported to be 93 % for EUS, which was greater than that of CT (53 %) and MRI (67 %)[58]. A meta-analysis revealed that CT and EUS were comparable in determining the resectability of PDAC, with high sensitivity and specificity[59].

    However, based on EUS for early diagnosis of PDAC, the experience and subjective factors affect on the accuracy, especially in the presence of chronic pancreatitis.Additionally, the availability of the EUS-FNA is restricted in community hospitals.Even when the EUS-FNA is utilized, the diagnosis can be also influenced by the operator's experience and the location of the needle insertion. In 2001 , Norton et al[60]reported the usefulness of neural network analysis of EUS images to distinguish between PDAC and chronic pancreatitis using 4 different image parameters. Although they provided a high sensitivity, the specificity was only 50 %. In 2008 , Das et al[61]applied techniques of digital image analysis to EUS images of the pancreas to develop a classification model that could differentiate PDAC from non-neoplastic tissue using ANN. The model accurately classified PDAC, with an AUC of 0 .93 and a 93 %sensitivity rate[61]. Digital analysis of EUS images is useful in differentiating PDAC from normal tissue and chronic inflammation. Given the possibility of real-time application, digital image analysis may become a helpful diagnostic modality in pancreatic diseases and may sometimes evade EUS-guided FNA. In another study,Zhanget al[62] differentiated between PDAC and normal tissue on EUS images.Regions of interest were selected from 216 images obtained from 153 cancer and 63 non-cancer patients, and a 97 .98 % sensitivity rate was obtained from the 29 features that were identified[62]. Zhu et al[63] conducted a computer-aided diagnosis utilizing EUS images of 262 PDAC and 126 chronic pancreatitis patients, from which 105 features were extracted. Sixteen of these features were selected for classification by a support vector machine and a 94 % sensitivity rate was obtained[63].

    EUS imaging is a common imaging method for diagnosing PDAC, and is often applied with FNA in distinguishing benign and malignant tumors. However, FNA is not available in all health centers. AI-assisted diagnosisviaEUS images should guide physicians toward more accurate and easier diagnosis.

    Collectively, AI can supplement radiologists to reduce miss rates, rather than replace them. The AI stands as a diagnostic tool to assist clinicians and radiologists in diagnosing PDAC. The application of AI in the diagnosis of PDAC has made substantial advances and is certainly improving.

    AI IN MOLECULAR/GENETIC SUBTYPE CLASSIFICATION

    Recent advances in biotechnology enable us to execute comprehensive genomic,transcriptomic, proteomic, and metabolomic analyses rapidly and cheaply. Such inclusive gene expression studies have uncovered subtypes of PDAC with biological and prognostic relevance. Collissonet al[9] proposed the categorization of PDACs into three subtypes: classical, quasi-mesenchymal (QM), and exocrine-like. The prognostic outcome of PDAC patients following operation and conventional medical treatment was notably better in the classical subtype than in patients with the QM subtype;patientss with the exocrine-like subtype displayed intermediate prognostic outcome between the two other subtypes[9]. Muckenhuber et al[64] subsequently reported that the most of PDAC can be categorized into two distinct subtypes based on transcriptome profiling and on immunohistochemical staining of cytokeratin-81 (KRT81 ) and hepatocyte nuclear factor-1 A (HNF1 a). The epithelial KRT81 -/HNF1 a-(double-negative) subtype (the so-called classical subtype) showed better survival and response to chemotherapy, notably to the FOLFIRINOX regimen, but not to a gemcitabine-based regimen. On the other hand, the epithelial KRT81 +/HNF1 asubtype (the so-called QM subtype) has worse OS. But, the QM subtype displays a better response to the gemcitabine-based regimen compared to the non-QM subtype[65]. These features encourage precision medicine based on individual molecular features.

    Recent developments in AI using medical image analysis such as radiomics reveal promising models of molecular phenotyping from imaging data. The radiomics approach can perform whole-tumor analytics without invasiveness. Kaissiset al[66 ,67]have reported on machine learning algorithms to preoperativelly predict molecular subtypes and survival risk in PDAC patients from MRI. However, the restricted availability of MRI data, overall decreased image quality, and the less-quantitative and unstandardized nature of MRI render obstacles to algorithm development and generalization. To reinfoce clinical application, Kaissiset al[68] extended their previous results to CT by training and validating an algorithm (random forest) capable of discriminating between the QM and the non-QM subtypes of PDAC. The advantages of CT comprise broad availability, fewer motion artifacts, and high standardization.Their retrospective study assessed baseline CT from 207 PDAC cases. By immunohistochemical staining for KRT81 and HNF1 a, the molecular subtype was determined as QMvsnon-QM. The random forest algorithm was used to predict the molecular subtype from the radiomic features. Then, the algorithm was applied to an independent cohort of histopathologically unclassifiable tumors. The classification algorithm achieved sensitivity, specificity, and AUC of 0 .84 , 0 .92 , and 0 .93 ,respectively. The median OS for predicted QM and non-QM tumors was 16 .1 and 20 .9 mo, respectively. The application of the algorithm to histopathologically unclassifiable tumors showed two groups with remarkably different survival (8 .9 and 39 .8 mo).Thus, the machine learning-based analysis of CT imaging provided the possibility of the prediction of molecular subtypes that is clinically relevant for prognostic outcome,permitting pre-operative stratification for precision medicine. This approach is encouraged by the fact that histopathological approachs are by default a significant underrepresentation of the tumor, since they are derived from a small sub-section of the tissue, and regions of differing molecular subtype are likely to coexist within the same tumor[69]. On the other hand, the radiomic approach enables whole-tumor assessment, providing better information required for precision therapy.

    Microsatellite instability (MSI) is a genomic property of cancers with defective DNA mismatch repair. Notably, MSI has been recognized as a biomarker for the favorable immune checkpoint blockade therapy response in cancer[70]. Most standard methods for examing MSI are based on DNA sequencing data and a few are based on mRNA expression data. Using RNA-Seq pan-cancer datasets for three cancer cohorts (colon,endometrial, and gastric cancers) from TCGA program, Liet al[19] established an algorithm called PreMSIm (Predicting MSI from mRNA) to predict MSI in cancer from the expression profiling of a 15 -gene panel. A benefit of mRNA-based over DNAbased MSI prediction algorithms is that mRNA data are closer to protein and phenotype than DNA data. Pathway analysis revealed that these genes were mainly involved in DNA damage repair (MLH1 and MSH4 ), gene expression (MLH1 ,HENMT1 , and RPL22 L1 ), cell cycle regulation (MLH1 , MSH4 , and HENMT1 ), and metabolism (NHLRC1 and RPL22 L1 ). Gene ontology analysis showed that these genes were involved in the biological processes of DNA repair (MLH1 , MSH4 , and RTF2 ),gene expression regulation (NHLRC1 and HENMT1 ), cell cycle (MLH1 , MSH4 ,RPL22 L1 , and RTF2 ), biogenesis (DDX27 , EPM2 AIP1 , NHLRC1 , and RNLS), metabolic process (HENMT1 , LYG1 , NHLRC1 , and SMAP1 ), and cell and organism development(SMAP1 , SHROOM4 , and TTC30 A). The PreMSIm algorithm provided high performance in predicting MSI using both RNA-Seq and microarray gene expression datasets[19]. Furthermore, PreMSIm showed superior or comparable performancevsother DNA- or mRNA-based methods. Liet al[19] comment that PreMSIm can be an alternative approach for identifying MSI. The introduction of machine learning algorithms such as this as a clinical decision support tool should be beneficial to predict molecular/genetic signatures that may help to stratify patients in clinical routines.

    AI IN RISK ASSESSMENT FOR PANCREATIC SURGERY

    In the pancreatic fields, the availability of AI in surgery is still very limited. An AIbased risk prediction model of postoperative complication has been reported[71 ,72].Postoperative pancreatic fistula (POPF) is a serious complication after pancreatoduodenectomy (PD). The fistula risk score (FRS), which consists of four variables —soft pancreas, small main pancreatic duct, high-risk pathology (PDAC or chronic pancreatitis), and massive intraoperative blood loss — is useful to predict clinically relevant POPF development after PD[73 ,74]. However, the score contains subjective factors related to surgeons. Therefore, an accurate and easy-to-use preoperative index is desired. Kambakambaet al[71] examined whether quantitative analysis of plain CT with five types of machine learning algorithms (k-nearest neighbors, sequential minimum optimization, multilayer perceptron, random forest, and C5 .0 ) could predict clinically relevant POPF in 110 patients from a single institution, and found that machine learning-based CT analysis provided an magnificent AUC of 0 .95 in predicting clinically relevant POPF[71]. Mu et al[72] tried to predict clinically relevant POPF after PD using a deep learning (CNN model) score derived from preoperative CT. The deep learning score offered significantly greater predictability compared to FRS in training (0 .85 vs 0 .78 in AUC, respectively), validation (0 .81 vs 0 .76 in AUC,respectively) and test (0 .89 vs 0 .73 in AUC, respectively) cohorts. In particular, in patients of intermediate risk (FRS 3 -6 ), the deep learning score achieved remarkably higher accuracy compared to FRS (test: 92 .1 % vs 65 .8 %, respectively). Interestingly, the deep learning score was independently associated with pancreatic fibrosis, diameter of main pancreatic duct and remnant volume in multivariate linear regression analysis.The automated scores reflected histomorphological features related to pancreatic duct,parenchymal fibrosis, and remnant pancreatic tissue volume. Thus, an AI model using preoperative CT represents a novel tool to predict clinically relevant POPF after PD,especially at intermediate risk levels. Such an AI system helps surgeons to optimize preoperative strategy.

    AI IN SURVIVAL PREDICTION AND RESPONSE TO CHEMOTHERAPY

    The potential of radiomics in prediction of clinically relevant conditions, such as expected OS or response to a specific therapy, has been reported in recent studies[75 ,76]: For instance, CT-derived radiomic features were useful to predict local disease control and OS in PDAC[75 ,76]. Entropy-related and cluster tendency features were described as predictive of OS in PDAC[76]. Zhang et al[77] proposed that a CNNbased survival model outperforms a Cox proportional hazard model-based radiomics pipeline in PDAC prognosis. This model provides a better fit for survival patterns based on CT images and overcomes the limitations of conventional survival models.Kaissiset al[66] reported that a machine learning algorithm (random forest) using MRI achieved 87 % sensitivity, 80 % specificity, and AUC 0 .9 for the prediction of above-vsbelow-median OS in the independent validation cohort. Alizadeh Savarehet al[40]have identified several circulating miRNAs as a diagnosis model in PDAC patients by analyzing microarray miRNA expression profiles from the Gene Expression Omnibus database. Three (hsa-mir-1469 , hsa-mir-663 a and hsa-mir-532 ) of five miRNAs with a high rank in the final model were comprehensively associated with the OS of patients with PDAC based on their up- or down-regulated expression patterns[40].

    Late diagnosis of PDAC can cause to lose the chance of surgical treatment and lead to a high mortality rate[78]. On the other hand, surgical treatments for PDAC can have a high morbidity and mortality rate. Therefore, the clinicians must weigh the potential survival advantage of the invasive treatment, the complications due to invasive treatment, and the impacts on the patient’s quality of life with and without treatment.

    Walczak and Velanovich[79] established ANN models that could accurately predict the 7 -mo survival of PDAC patients using 14 clinical variables including eight SF-36 domain values, both with and without surgical resection, at 91 % sensitivity and 38 %specificity. The ANN model to predict 7 -mo survival consisted of age, sex, the eight domains of quality of life measurements from the SF-36 , the stage of the cancer,whether or not a resection had taken place, if any adjuvant therapy had been given,and time in months since diagnosis. The quality of life domains from the SF-36 are bodily pain, vitality, physical functioning, social functioning, role-physical, roleemotional, general health, and mental health. Such an ANN model for predicting the survival of PDAC patients helps physicians and patients to reduce anticipated regret from treatment decisions including observation. This information may be useful for patients and surgeons in determining invasive treatment plans to minimize regret and improve the patients' quality of life.

    Neoadjuvant therapy may provide improved survival of PDAC patients; but,determining the efficacy is difficult. Watsonet al[80] hypothesized that a deep learning(CNN) model could predict the tumor response to neoadjuvant therapy using CT and CA19 -9 . A total of 81 cases were divided between partial responder (333 images) and non-responder (443 images). The model using only the deep learning model had an AUC of 0 .738 , whereas a hybrid model incorporating a decrease in CA19 -9 of 10 % in addition to the deep learning model had an AUC of 0 .785 . CA19 -9 reduction alone was not an effective predictor of the response to neoadjuvant therapy, with an AUC of 0 .564 . A deep learning model can predict the pathological response to neoadjuvant therapy for PDAC patients, and the model is amended with the incorporation of decreases in serum CA19 -9 . Abraham et al[81] investigated the clinical relevance of a machine learning-derived signature in predicting the responses from first-line oxaliplatin-based chemotherapy in PDAC and advanced colorectal cancer. The machine learning-derived signature was effective for metastatic colorectal cancer, but not for PDAC. AI has already been applied to match biological information with chemical properties of specific drugs to predict the response to these specific agents in cancers[82].

    In the near future, the combined analysis of clinical variables, less-invasive biological samples, and radiological features through machine learning should be able to simulate responses to chemotherapy and patient survival. On the other hand,radiological features and biological tissue can be variable in response to the treatment including chemotherapy and radiotherapy. In particular, PDAC has a high potential for acquired drug resistance. During sequential treatment, good communication and the accumulation of knowledge from various fields such as gastroenterology,radiology, oncology, computer science, and pathology must will be required to fight this deadly disease.

    Figure 2 Future perspectives in the management of pancreatic ductal adenocarcinoma by artificial intelligence. AI: Artificial intelligence;PDAC: Pancreatic ductal adenocarcinoma.

    LIMITATIONS AND FUTURE PERSPECTIVES

    A major limitation is the lack of adequate standardization. Universal and uniform protocols for data collection, data quality, storage, processing, reproduction, and analysis must be established. For instance, ANNs can be trained to appropriately categorize histologic slides of pancreatic biopsies. However, the trained ANNs may underperform, or not perform at all, when the prepared slides are fixed and stained in a different manner. Development of universal and uniform protocols during data and sample processing will be required for medical AI to be feasible. Further improvement of the technology is also essential for medical AI in clinical practice.

    AI in the medical field should become an indispensable tool to reduce human error.Because of human limitations, we cannot achieve zero errors. Furthermore, it is timeconsuming to train professional radiologists, gastroenterologists, oncologists, and pathologists. Combined work by experts from multiple fields will be needed to establish feasible medical AI systems in clinical practice. With further research, AI must have a great impact on the diagnosis and treatment of PDAC in near future.Ultimately, a sequential approach involving risk prediction, diagnosis, treatment, and survival prediction using IA will realize timely and consecutive precision medicine and lead to improved prognosis in PDAC (Figure 2 ). Dr. William Osler stated:“Medicine is a science of uncertainty and an art of probability.” This is still true in medical AI, which is also “a science of uncertainty and an art of probability.”However, the degree of uncertainty and probability will consistently shrink with the advance of AI technology and cooperation among various experts. While AI applications in PDAC are still in the early stage of development, further research must lead to great advances in screening, early diagnosis, and treatment.

    CONCLUSION

    Here we summarize the current advances of AI in PDAC. AI-based omics analyses are likely to be the next alternative approach to overcome this poor-prognostic disease by the discovery of biomarkers for early detection, molecular/genomic subtyping, and treatment guidance, and by the improved prediction of recurrence and survival. How to entirely utilize “big data” is a new challenge for physicians and researchers in the era of precision medicine. On the other hand, AI will not entirely act for doctors —human beings and machines working harmoniously together is the ideal state that results in excellent performance. Although AI data reveal that the diagnostic accuracy of deep learning models is better than that of radiologists, the aim in this field is to develop a helpful tool to aid radiologists in making effective and accurate diagnoses,not to be a replacement for doctors. To facilitate AI-based omics analyses, multidisciplinary collaboration between physicians, basic scientists, radiologists, statisticians, and engineers is mandatory. To further validate the clinical relevance of AI systems, next step is to conduct a prospective study based on multicenter clinical data. We believe that breakthroughs will soon emerge to fight this deadly disease using AI-navigated precision medicine.

    1024视频免费在线观看| 国产色视频综合| 很黄的视频免费| 欧洲精品卡2卡3卡4卡5卡区| 国产成人免费无遮挡视频| 黄色毛片三级朝国网站| 丰满饥渴人妻一区二区三| 亚洲国产毛片av蜜桃av| 色综合站精品国产| 亚洲av熟女| 99精品久久久久人妻精品| 午夜成年电影在线免费观看| 9191精品国产免费久久| 精品国产超薄肉色丝袜足j| 亚洲国产精品999在线| 国产欧美日韩精品亚洲av| 国产成人精品久久二区二区91| 视频区图区小说| 伦理电影免费视频| 在线十欧美十亚洲十日本专区| 国产深夜福利视频在线观看| 国产精品九九99| 免费看十八禁软件| 搡老乐熟女国产| a级毛片黄视频| 亚洲国产毛片av蜜桃av| 免费女性裸体啪啪无遮挡网站| 亚洲人成电影免费在线| 啦啦啦在线免费观看视频4| 又紧又爽又黄一区二区| 国产一卡二卡三卡精品| 国产精品偷伦视频观看了| 久久伊人香网站| 不卡av一区二区三区| 伊人久久大香线蕉亚洲五| 亚洲精品久久成人aⅴ小说| 91av网站免费观看| 日韩有码中文字幕| 麻豆一二三区av精品| 亚洲精品在线美女| 88av欧美| 国产精品成人在线| 人妻丰满熟妇av一区二区三区| 一级黄色大片毛片| 一进一出好大好爽视频| 嫁个100分男人电影在线观看| 自拍欧美九色日韩亚洲蝌蚪91| 中文字幕高清在线视频| av天堂在线播放| 国产三级黄色录像| 两性夫妻黄色片| 亚洲欧洲精品一区二区精品久久久| 色老头精品视频在线观看| 久久人人精品亚洲av| 亚洲第一青青草原| 制服诱惑二区| 最近最新中文字幕大全电影3 | 一夜夜www| 久久久精品国产亚洲av高清涩受| 国产精品野战在线观看 | bbb黄色大片| 黄色怎么调成土黄色| 国产一区二区三区视频了| 少妇被粗大的猛进出69影院| 男人的好看免费观看在线视频 | 99在线人妻在线中文字幕| 欧美乱妇无乱码| 国产aⅴ精品一区二区三区波| 777久久人妻少妇嫩草av网站| 巨乳人妻的诱惑在线观看| 欧美日韩乱码在线| 亚洲精品国产一区二区精华液| 亚洲va日本ⅴa欧美va伊人久久| 午夜免费成人在线视频| 久久久国产精品麻豆| 在线观看免费午夜福利视频| 午夜免费鲁丝| 黑人巨大精品欧美一区二区蜜桃| 久久人妻福利社区极品人妻图片| 成熟少妇高潮喷水视频| 久久国产精品影院| 国产精品二区激情视频| 国产极品粉嫩免费观看在线| 99国产精品99久久久久| 亚洲自拍偷在线| 欧美日韩亚洲综合一区二区三区_| 性少妇av在线| 国产精品国产高清国产av| 美女大奶头视频| 日本免费a在线| 国产精品亚洲av一区麻豆| 欧美日韩国产mv在线观看视频| 亚洲av成人不卡在线观看播放网| 午夜亚洲福利在线播放| 亚洲国产中文字幕在线视频| 天堂俺去俺来也www色官网| 午夜免费观看网址| 真人一进一出gif抽搐免费| 国产精品一区二区在线不卡| 久久国产精品影院| 国产黄a三级三级三级人| 一级作爱视频免费观看| 看黄色毛片网站| 久久人人97超碰香蕉20202| 国产一区二区在线av高清观看| 一进一出抽搐动态| 欧美日韩国产mv在线观看视频| 婷婷精品国产亚洲av在线| 国产精品爽爽va在线观看网站 | 天堂中文最新版在线下载| 欧美中文日本在线观看视频| 又紧又爽又黄一区二区| 1024香蕉在线观看| 一区在线观看完整版| 成人18禁高潮啪啪吃奶动态图| 亚洲精品成人av观看孕妇| 在线观看免费视频网站a站| 免费搜索国产男女视频| 男女高潮啪啪啪动态图| 亚洲专区国产一区二区| a级片在线免费高清观看视频| 这个男人来自地球电影免费观看| 黄片播放在线免费| 麻豆久久精品国产亚洲av | 精品国内亚洲2022精品成人| 99久久人妻综合| av有码第一页| 99精品久久久久人妻精品| 色综合婷婷激情| 大型黄色视频在线免费观看| 日韩三级视频一区二区三区| 99热国产这里只有精品6| 法律面前人人平等表现在哪些方面| 欧美激情久久久久久爽电影 | 亚洲av熟女| 亚洲国产中文字幕在线视频| 亚洲精品中文字幕在线视频| 亚洲人成77777在线视频| 免费在线观看亚洲国产| 日日夜夜操网爽| 免费在线观看影片大全网站| 国产精品免费一区二区三区在线| 在线观看日韩欧美| 99久久99久久久精品蜜桃| 日韩精品青青久久久久久| 亚洲av电影在线进入| 日本撒尿小便嘘嘘汇集6| 午夜91福利影院| 一级黄色大片毛片| 亚洲熟妇熟女久久| av片东京热男人的天堂| 色婷婷久久久亚洲欧美| 久久中文看片网| 麻豆国产av国片精品| 成人精品一区二区免费| 精品国产一区二区三区四区第35| 亚洲一区二区三区欧美精品| 色播在线永久视频| 日韩欧美一区视频在线观看| 国产欧美日韩一区二区精品| 老司机亚洲免费影院| 他把我摸到了高潮在线观看| 两人在一起打扑克的视频| 欧美人与性动交α欧美软件| 深夜精品福利| 国产亚洲欧美98| 欧美日韩精品网址| 亚洲av日韩精品久久久久久密| 91麻豆av在线| 12—13女人毛片做爰片一| 日韩视频一区二区在线观看| 亚洲情色 制服丝袜| 亚洲伊人色综图| 国产成人精品久久二区二区91| 亚洲情色 制服丝袜| 人人妻,人人澡人人爽秒播| 欧美成人性av电影在线观看| 可以在线观看毛片的网站| 久久人人精品亚洲av| 一边摸一边抽搐一进一小说| 欧美乱色亚洲激情| 一二三四社区在线视频社区8| 亚洲欧美激情综合另类| 亚洲中文字幕日韩| 日本免费a在线| 国产aⅴ精品一区二区三区波| 亚洲av成人不卡在线观看播放网| 国产黄色免费在线视频| av电影中文网址| 久久精品国产亚洲av香蕉五月| 国产精品成人在线| 久久精品亚洲熟妇少妇任你| 亚洲视频免费观看视频| 免费搜索国产男女视频| 国产成人精品在线电影| 久久久精品国产亚洲av高清涩受| 欧美人与性动交α欧美软件| 日本精品一区二区三区蜜桃| 久久久久国内视频| 最近最新中文字幕大全电影3 | 国产有黄有色有爽视频| aaaaa片日本免费| 看黄色毛片网站| 80岁老熟妇乱子伦牲交| 高清黄色对白视频在线免费看| av片东京热男人的天堂| 好看av亚洲va欧美ⅴa在| 99久久久亚洲精品蜜臀av| 欧美日韩中文字幕国产精品一区二区三区 | 婷婷丁香在线五月| 欧美人与性动交α欧美软件| 99国产极品粉嫩在线观看| 亚洲精品粉嫩美女一区| 人人妻人人澡人人看| 久久人人爽av亚洲精品天堂| 亚洲第一av免费看| 大型av网站在线播放| x7x7x7水蜜桃| 看黄色毛片网站| 纯流量卡能插随身wifi吗| 在线看a的网站| 首页视频小说图片口味搜索| 在线国产一区二区在线| 色在线成人网| 亚洲狠狠婷婷综合久久图片| 两性夫妻黄色片| 精品国产国语对白av| 亚洲午夜精品一区,二区,三区| 村上凉子中文字幕在线| 亚洲国产精品一区二区三区在线| 免费av中文字幕在线| 亚洲专区中文字幕在线| 视频区欧美日本亚洲| 亚洲人成伊人成综合网2020| 咕卡用的链子| 欧美在线黄色| 亚洲五月婷婷丁香| 久久热在线av| 亚洲专区中文字幕在线| 中文字幕另类日韩欧美亚洲嫩草| 日日摸夜夜添夜夜添小说| 三上悠亚av全集在线观看| 久久久水蜜桃国产精品网| 午夜精品在线福利| 精品久久久精品久久久| 日韩三级视频一区二区三区| 精品国产一区二区久久| 热99国产精品久久久久久7| 99国产极品粉嫩在线观看| 国产精品日韩av在线免费观看 | 亚洲精品av麻豆狂野| 大型黄色视频在线免费观看| 亚洲九九香蕉| 欧美另类亚洲清纯唯美| 动漫黄色视频在线观看| а√天堂www在线а√下载| 国产成人欧美在线观看| 一二三四在线观看免费中文在| 一区福利在线观看| 国产熟女午夜一区二区三区| 高清欧美精品videossex| 亚洲av成人av| 国产97色在线日韩免费| 午夜精品国产一区二区电影| 女生性感内裤真人,穿戴方法视频| 男女高潮啪啪啪动态图| 亚洲成人精品中文字幕电影 | aaaaa片日本免费| 51午夜福利影视在线观看| 免费少妇av软件| 在线看a的网站| 国产单亲对白刺激| 9色porny在线观看| 美女国产高潮福利片在线看| 精品一区二区三卡| 精品人妻在线不人妻| 国产精品久久久人人做人人爽| 久久精品aⅴ一区二区三区四区| 美女高潮喷水抽搐中文字幕| 男女床上黄色一级片免费看| 视频区欧美日本亚洲| 国产成人影院久久av| 热99re8久久精品国产| 婷婷丁香在线五月| 丁香六月欧美| 亚洲欧美精品综合一区二区三区| 97碰自拍视频| 男女床上黄色一级片免费看| 精品免费久久久久久久清纯| 成年人黄色毛片网站| 久久久久国产一级毛片高清牌| 国产99久久九九免费精品| 精品福利观看| 麻豆久久精品国产亚洲av | 国产精品日韩av在线免费观看 | 可以免费在线观看a视频的电影网站| 久久精品亚洲精品国产色婷小说| 黄色女人牲交| 国产激情久久老熟女| 侵犯人妻中文字幕一二三四区| 国产一区二区三区综合在线观看| x7x7x7水蜜桃| 亚洲av五月六月丁香网| 午夜亚洲福利在线播放| 国产aⅴ精品一区二区三区波| 激情视频va一区二区三区| 19禁男女啪啪无遮挡网站| 欧美久久黑人一区二区| 91字幕亚洲| 亚洲欧美一区二区三区黑人| 天堂影院成人在线观看| 精品人妻在线不人妻| 国产精品日韩av在线免费观看 | 中出人妻视频一区二区| 丝袜在线中文字幕| 琪琪午夜伦伦电影理论片6080| 国产成人av激情在线播放| 黑人巨大精品欧美一区二区蜜桃| 啪啪无遮挡十八禁网站| 可以在线观看毛片的网站| 97人妻天天添夜夜摸| 99国产综合亚洲精品| 美女扒开内裤让男人捅视频| 久久香蕉精品热| 久久香蕉国产精品| 99久久国产精品久久久| 亚洲精品国产区一区二| 久久精品国产亚洲av高清一级| 法律面前人人平等表现在哪些方面| 国产成人系列免费观看| tocl精华| 日韩国内少妇激情av| 国内毛片毛片毛片毛片毛片| 日本三级黄在线观看| 动漫黄色视频在线观看| 亚洲中文av在线| 久9热在线精品视频| 热re99久久精品国产66热6| 久久久精品欧美日韩精品| 久久伊人香网站| 亚洲精品久久成人aⅴ小说| 香蕉国产在线看| 热re99久久国产66热| 搡老岳熟女国产| 国产精品亚洲av一区麻豆| 欧美日韩黄片免| 亚洲成av片中文字幕在线观看| 国产片内射在线| 亚洲va日本ⅴa欧美va伊人久久| 涩涩av久久男人的天堂| 亚洲国产精品sss在线观看 | videosex国产| 欧美乱妇无乱码| www.熟女人妻精品国产| 国产精品一区二区在线不卡| 一级a爱视频在线免费观看| 男女下面进入的视频免费午夜 | 无遮挡黄片免费观看| 这个男人来自地球电影免费观看| 国内久久婷婷六月综合欲色啪| 亚洲欧美一区二区三区久久| 亚洲自偷自拍图片 自拍| 国产精品免费一区二区三区在线| 免费高清在线观看日韩| 精品国产一区二区久久| 热re99久久国产66热| 伊人久久大香线蕉亚洲五| 午夜免费观看网址| 久久精品亚洲av国产电影网| 国产精品一区二区在线不卡| 亚洲成人精品中文字幕电影 | 51午夜福利影视在线观看| 国产亚洲精品久久久久5区| 久久久国产成人免费| 黑人猛操日本美女一级片| 一边摸一边抽搐一进一出视频| 日韩成人在线观看一区二区三区| 亚洲av日韩精品久久久久久密| 国产欧美日韩综合在线一区二区| 国产精品一区二区免费欧美| 国产视频一区二区在线看| 黄色女人牲交| 国产成人av教育| 香蕉久久夜色| av天堂在线播放| 丝袜美腿诱惑在线| 国产亚洲欧美98| 国产成+人综合+亚洲专区| 身体一侧抽搐| av视频免费观看在线观看| 性色av乱码一区二区三区2| 久久天躁狠狠躁夜夜2o2o| 超碰成人久久| 高清欧美精品videossex| 99国产精品99久久久久| 国产精品98久久久久久宅男小说| 少妇粗大呻吟视频| 色哟哟哟哟哟哟| 母亲3免费完整高清在线观看| 首页视频小说图片口味搜索| 亚洲午夜理论影院| 亚洲精品在线观看二区| 国产亚洲欧美在线一区二区| 亚洲aⅴ乱码一区二区在线播放 | 麻豆一二三区av精品| 国产成人av激情在线播放| 老司机深夜福利视频在线观看| 天堂俺去俺来也www色官网| 一级a爱片免费观看的视频| 久久精品人人爽人人爽视色| 日本一区二区免费在线视频| 一边摸一边做爽爽视频免费| 男女之事视频高清在线观看| 色婷婷久久久亚洲欧美| 亚洲久久久国产精品| 久久精品国产99精品国产亚洲性色 | 男人舔女人下体高潮全视频| 国产欧美日韩综合在线一区二区| 九色亚洲精品在线播放| 男人的好看免费观看在线视频 | 亚洲成人免费av在线播放| 在线观看午夜福利视频| 好看av亚洲va欧美ⅴa在| 美女午夜性视频免费| 性少妇av在线| 热re99久久精品国产66热6| 久久亚洲精品不卡| 可以免费在线观看a视频的电影网站| 久久婷婷成人综合色麻豆| 日韩av在线大香蕉| 成年女人毛片免费观看观看9| 国产又爽黄色视频| 精品无人区乱码1区二区| 激情在线观看视频在线高清| 精品久久久久久久毛片微露脸| 久久精品亚洲精品国产色婷小说| 日本黄色日本黄色录像| 国产人伦9x9x在线观看| 久久国产精品影院| 91九色精品人成在线观看| 国产真人三级小视频在线观看| 69精品国产乱码久久久| 激情在线观看视频在线高清| 日日干狠狠操夜夜爽| 美女福利国产在线| 久久国产精品男人的天堂亚洲| 老司机福利观看| 女人高潮潮喷娇喘18禁视频| 欧美成狂野欧美在线观看| 欧美乱码精品一区二区三区| 久久99一区二区三区| 麻豆一二三区av精品| 在线免费观看的www视频| 国产亚洲欧美98| av欧美777| x7x7x7水蜜桃| 久久人人97超碰香蕉20202| 国产成人欧美在线观看| 久久欧美精品欧美久久欧美| 麻豆国产av国片精品| 国产伦一二天堂av在线观看| 男女下面插进去视频免费观看| av电影中文网址| 久久久水蜜桃国产精品网| 精品久久久精品久久久| 视频区欧美日本亚洲| 两个人看的免费小视频| 欧美激情极品国产一区二区三区| 成人影院久久| 在线观看免费视频网站a站| 人人澡人人妻人| 两个人免费观看高清视频| 国产97色在线日韩免费| 国产av在哪里看| 欧美成人免费av一区二区三区| 久久久久亚洲av毛片大全| 麻豆国产av国片精品| 欧美日本亚洲视频在线播放| 午夜精品久久久久久毛片777| 欧美成人午夜精品| 久久久久久久久久久久大奶| 丝袜在线中文字幕| 高清毛片免费观看视频网站 | 嫩草影视91久久| www国产在线视频色| 精品电影一区二区在线| 国产欧美日韩一区二区精品| 亚洲欧美日韩无卡精品| 成人国语在线视频| 欧美+亚洲+日韩+国产| 男人的好看免费观看在线视频 | 一边摸一边抽搐一进一出视频| 又大又爽又粗| 9热在线视频观看99| 99精国产麻豆久久婷婷| 国产精品免费视频内射| 高清黄色对白视频在线免费看| 91九色精品人成在线观看| 免费高清视频大片| 9色porny在线观看| 男女下面进入的视频免费午夜 | 看黄色毛片网站| 久久精品国产清高在天天线| 中文字幕高清在线视频| 99在线人妻在线中文字幕| 高清在线国产一区| 亚洲少妇的诱惑av| 国产97色在线日韩免费| 宅男免费午夜| 黄色毛片三级朝国网站| 精品福利永久在线观看| 老司机靠b影院| 中文字幕色久视频| 亚洲成人免费av在线播放| 国产麻豆69| 午夜福利一区二区在线看| 在线av久久热| 日韩欧美国产一区二区入口| www.精华液| 国产在线观看jvid| 免费在线观看亚洲国产| 国产精品综合久久久久久久免费 | 欧美日韩乱码在线| 9191精品国产免费久久| 久久天躁狠狠躁夜夜2o2o| 国产精品免费视频内射| 啪啪无遮挡十八禁网站| 国产欧美日韩一区二区三区在线| 在线观看日韩欧美| 国产精品免费视频内射| 极品人妻少妇av视频| 热99国产精品久久久久久7| 在线天堂中文资源库| 欧美久久黑人一区二区| 国产精品二区激情视频| 久久人人爽av亚洲精品天堂| 久久精品aⅴ一区二区三区四区| 免费一级毛片在线播放高清视频 | 精品乱码久久久久久99久播| 高清在线国产一区| 亚洲片人在线观看| 国产成人精品久久二区二区免费| 国产精品九九99| 男男h啪啪无遮挡| 麻豆av在线久日| 午夜两性在线视频| 国产黄色免费在线视频| 女人高潮潮喷娇喘18禁视频| 午夜老司机福利片| 纯流量卡能插随身wifi吗| 国产激情久久老熟女| 国产又色又爽无遮挡免费看| 免费一级毛片在线播放高清视频 | 19禁男女啪啪无遮挡网站| 欧美日韩瑟瑟在线播放| 丝袜美腿诱惑在线| 老汉色∧v一级毛片| 国产精华一区二区三区| ponron亚洲| 色尼玛亚洲综合影院| 国产一卡二卡三卡精品| 欧美乱色亚洲激情| 久久中文字幕人妻熟女| 999久久久精品免费观看国产| 18美女黄网站色大片免费观看| 亚洲人成网站在线播放欧美日韩| 亚洲欧美激情综合另类| 国产亚洲精品第一综合不卡| 日韩大码丰满熟妇| 女人被躁到高潮嗷嗷叫费观| 男人的好看免费观看在线视频 | 1024视频免费在线观看| 人人妻,人人澡人人爽秒播| 无人区码免费观看不卡| 18禁国产床啪视频网站| 久久热在线av| 亚洲一码二码三码区别大吗| 嫩草影视91久久| 欧美黄色淫秽网站| 中文字幕人妻丝袜一区二区| 久久人人爽av亚洲精品天堂| 国产成人精品久久二区二区91| 色老头精品视频在线观看| 无人区码免费观看不卡| 亚洲欧美激情在线| 亚洲欧美精品综合久久99| 国产精品日韩av在线免费观看 | 亚洲欧美精品综合一区二区三区| 美女 人体艺术 gogo| 黑人巨大精品欧美一区二区蜜桃| 黄色片一级片一级黄色片| 18禁国产床啪视频网站| 91老司机精品| 高清黄色对白视频在线免费看| 女性被躁到高潮视频| a级毛片在线看网站| 久久久国产欧美日韩av| 亚洲男人的天堂狠狠| 黄色女人牲交| 中文字幕精品免费在线观看视频| 日韩欧美三级三区| 热99国产精品久久久久久7| 69av精品久久久久久| av天堂在线播放| 性欧美人与动物交配| 美女高潮到喷水免费观看| 中文亚洲av片在线观看爽| 99精品久久久久人妻精品| 久久天堂一区二区三区四区| 精品国内亚洲2022精品成人| 亚洲一区二区三区欧美精品| 黄网站色视频无遮挡免费观看| 精品久久蜜臀av无| 丰满的人妻完整版| 在线十欧美十亚洲十日本专区|